Navigation Links
Thomson Scientific Introduces a New Quarterly Report Identifying the 'Movers and Shakers' in the U.S. Generics Industry
Date:1/8/2008

Report Draws On Strategic Intelligence and Competitive Analysis Information

From Newport Horizon Global(TM)

PHILADELPHIA and LONDON, Jan. 9 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, has released the first issue of Movers and Shakers. This newest report in the Pharma Matters series analyzes the U.S. generics market from July to September 2007, profiles some of the companies breaking into the market, and highlights molecule patents currently being challenged.

Movers and Shakers reviews the U.S. generics market using strategic intelligence and competitive analysis information drawn from Thomson Scientific's Newport Horizon Global, the critical product targeting and global business development system from the industry authority on the global generics market, in order to assess one of the world's most important pharmaceutical markets.

"Because of the dynamic nature of the generics market in the U.S., the common perception is that the market is relatively easy to break into," said Kate Kuhrt, director, Generics and API Intelligence, Thomson Scientific. "However, our research has shown that there is huge competition between the incumbents and new companies vying for a slice of the market, and clearly there will be winners and losers. Ours is the first quarterly report to identify the real 'movers and shakers' within the generics market."

The first quarterly report covers the period of July to September 2007, and highlights the key indicators of the state of play of the industry. These are:

Abbreviated New Drug Applications (ANDA): An ANDA is the first step in the process a company needs to follow in order to release a generic drug in the U.S. and is submitted to the FDA to prove that the generic version is equivalent to the brand name drug (reference listed drug).

Paragraph IV challenges: A generic company may obtain FDA approval before patent expiry if it certifies its product does not infringe the listed patents or the patents are invalid (paragraph IV certification). In addition, the first company to file an ANDA with paragraph IV certification is awarded a 180-day period of exclusivity for the ensuing generic product, giving the filer an important competitive advantage. Bioequivalent generic versions of drugs that are not protected by patents can be produced and marketed in the U.S. by any company, subject to FDA approval.

Who Are the Movers and Shakers This Quarter?

Molecules recently exposed to paragraph IV challenges: Big Pharma companies such as sanofi-aventis, Eli Lilly, Hoffmann-La Roche and AstraZeneca all saw challenges in the period from July to September on molecules they have patented.

Companies taking their first steps into the US generics industry: The report highlights companies that were felt to be of significant interest. This quarter, the report focuses on Dabur India Ltd, who launched a Paragraph IV challenge on the drug oxaliplatin, Zhejiang Huahai Pharmaceutical Group Co Ltd, a Chinese company that has received tentative approval for nevirapine 200mg tablets under the President's Emergency Plan for Aids Relief (PEPAR) program, and GeneraMedix Pharmaceuticals Inc., an American company based in New Jersey that has received FDA approval for a selection of new products.

"The global stakes involved in the US generics market become evident when you see that the top country filing ANDAs in the US is India, and the company recorded as having the most Paragraph IV patent challenges is Teva, an Israeli Pharma company," added Kuhrt. "Clearly, the message is that American companies cannot presume that they will have a home advantage in this market."

About This Quarterly Report:

Data for this report was compiled and analyzed using Newport Horizon Global(R) a critical product targeting and global business development system from Thomson Scientific. Created specifically for generic pharmaceutical companies and strategic API manufacturers, it allows them to identify and evaluate product opportunities worldwide, ensuring they will be the first to find the generic product and niche opportunity, first to make the deal, and first to get to market.

For a copy of the full report with analysis, visit:

(To view the following url, please copy and paste it into a new browser.) http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/m-a-s-jul- sep07.pdf

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE The Thomson Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
2. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
3. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
4. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
5. Thomson Scientific Takes a Fresh Look at Multiauthor Papers
6. Thomson Healthcare Study Finds That Hospitals Delivering High-Quality Heart Care Are Efficient and Cost Effective, Too
7. Thomson Scientific Publishes Who Is Making The Biggest Splash? - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007
8. Thomson Healthcare Launches Application That Assesses Physician Performance
9. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
10. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
11. Thomson Scientific Ranks Australian Universities and Research Institutes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... 2017 , ... A New York high tech innovator and a Canadian not-for-profit ... of Artificial Intelligence (AI) in helping nudge men forward to be more proactive about ... of the Canadian Men’s Health Foundation (CMHF), whose mission is to inspire men to ...
(Date:5/28/2017)... ... ... HYPERAMS, LLC announced it will perform the inventory liquidation of ... The sale began this week and the inventory is expected to sell quickly. ... medical accessories, including blood pressure cuffs, stethoscopes, CPR masks, as well as blank polos, ...
(Date:5/28/2017)... ... 28, 2017 , ... Viewers likely know Rob Lowe from such 80s hits ... for his work on NBC’s The West Wing and Parks and Recreation. But recently, ... “Informed,” which puts the spotlight on important modern-day issues that face today’s society. One ...
(Date:5/27/2017)... ... ... In any business, follow up is critical to success. It is the same ... there will always be some patients who can’t or won’t make a immediate decision. ... it comes to presenting treatment. After the patient leaves, most practices end up ...
(Date:5/26/2017)... NY (PRWEB) , ... May 26, 2017 , ... Mediaplanet ... & Wound Care" campaign in USA Today, which will educate readers on how to ... of the campaign, a large focus is placed on melanoma. Dancing with the Stars ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: